CIDRAP newsletters options
The authors found strong evidence of viral circulation before initial case detection in each affected world region.
The patients had both consumed potentially contaminated raw date palm sap, a known risk factor for contracting the virus.
The report calls for progress in 4 key areas: antibiotic manufacturing, antibiotic research and development, access, and appropriate use.
Danish research and development company GlyProVac will receive $467,000 to develop a maternal vaccine that targets a leading cause of neonatal sepsis.
Dengue cases in the Americas so far this year are outpacing last year's record activity.
Data on Salmonella and Campylobacter bacteria from people and food-producing animals show high levels of resistance to commonly used antibiotics.
Among adults 65 years and older, vaccine effectiveness was 54% in the first 7 to 59 days.
COVID-19 survivors whose symptoms had resolved in less than 4 weeks or at least 12 weeks had comparable small deficits in cognitive function.
Willingness to get their child vaccinated against Lyme was associated with higher parental education.
For the first time, the mid-season report from four VE networks covers both pediatric and adult age groups.
Of the 135 isolates, 55% were identified as containing multi-drug resistant E coli.
Researchers saw sustained efficacy against both severe and less severe symptoms.
Patients undergoing gastrointestinal surgery at safety net hospitals had a nearly 30% increased risk of SSIs compared with all hospitals.
The group settled on stronger wording to clarify advice for patients and simplify decisions for clinicians.
The authors found a 78% reduction in risk of hospitalization among patients who had 3 doses of vaccine as well as Paxlovid.
In March 2020, home deaths rose 8%, but only 6% in the most economically deprived patients.
Bacteriophage therapy helped suppress a recurring bloodstream infection that wasn't responding to antibiotics, but an immune response was too much to overcome.
The recommendation applies to people traveling to outbreak areas and others at extra risk from the virus.
There was also a lower 3-month mortality (31% vs 39%) for the antiplatelet-therapy group.
The first-in-class, novel antibiotic showed non-inferiority to the current standard-of-care gonorrhea treatment.
